Skip to main content

Day: March 27, 2026

CenterPoint Energy, Inc. to Host Webcast of First Quarter 2026 Earnings Conference Call on April 23, 2026

Houston, TX, March 27, 2026 (GLOBE NEWSWIRE) — Date:  April 23, 2026 Time:  7:00 a.m. Central time or 8:00 a.m. Eastern time Listen via internet:  http://investors.centerpointenergy.com/ Click “Investors”, and click the link “CenterPoint Energy, Inc. First Quarter 2026 Earnings Conference Call” As the only investor-owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Louisiana, Minnesota, Mississippi, Ohio and Texas. As of December 31, 2021, the company owned approximately $38 billion in assets. With approximately 9,400 employees, CenterPoint Energy and its predecessor companies have...

Continue reading

Sotherly Hotels Inc. Announces Intention to List on OTC Market Platform, Voluntarily Delist from Nasdaq and Continue SEC Reporting

WILLIAMSBURG, Va., March 27, 2026 (GLOBE NEWSWIRE) — Sotherly Hotels Inc. (the “Company” or “Sotherly”), a real estate investment trust, announced today that its Board of Directors has approved the voluntary withdrawal of the listing of the Company’s shares of 8.0% Series B Cumulative Redeemable Perpetual Preferred Stock, 7.875% Series C Cumulative Redeemable Perpetual Preferred Stock and 8.25% Series D Cumulative Redeemable Perpetual Preferred Stock (collectively, the “Preferred Stock”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Company expects to file a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about April 7, 2026 for the delisting of the Preferred Stock from Nasdaq and the deregistration of the Preferred Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange...

Continue reading

BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency

Discloses “Going Concern” Explanatory Paragraph in Auditor’s Report NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the “NYSE American”) that the Company was not in compliance with the NYSE American’s continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the “Company Guide”), requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing...

Continue reading

TRG Latin America Acquisitions Corp. Announces Closing of Partial Exercise of IPO Over-Allotment Option

New York, NY, March 27, 2026 (GLOBE NEWSWIRE) —  TRG Latin America Acquisitions Corp. (the “Company”) (NASDAQ: TRGSU), announced today that the underwriter of its previously consummated initial public offering has partially exercised its option to purchase an additional 632,000 units at the public offering price of $10.00 per unit, resulting in additional gross proceeds of $6,320,000. The underwriter has a remaining option to purchase up to 2,368,000 additional units. After giving effect to this partial exercise of the over-allotment option, the total number of units sold in the public offering increased to 20,632,000 units, resulting in total gross proceeds of $206,320,000 for the Company’s initial public offering. Each unit consists of one Class A ordinary share and one right entitling the holder thereof to receive one-tenth of...

Continue reading

Total Return Securities Fund Announces Annual Meeting

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Total Return Securities Fund (the “Fund”) (NYSE: SWZ) announced today that its 2026 Annual Meeting of Stockholders will be held at 2:00 p.m. Eastern Time on Thursday, June 11, 2026 at the office of Bulldog Investors LLP, 250 Pehle Avenue, Suite 708, Saddle Brook, NJ 07663. Stockholder proposals intended to be presented at the 2026 Annual Meeting in accordance with Rule 14a-8 of the Securities and Exchange Act of 1934 must be received by the Fund by April 17, 2026 in proper form in order to be considered for inclusion in the Fund’s Proxy Statement and form of Proxy for that meeting.  In addition, if an eligible stockholder desires to bring proposals (including Director nominations) before the 2026 Annual Meeting, appropriate written notice of such proposals must be received by the...

Continue reading

Forte Minerals Provides Updates on Alto Ruri and Pucarini Projects, Peru

VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) — Forte Minerals Corp. (“Forte” or the “Company”) (CSE: CUAU) (OTCQB: FOMNF) (Frankfurt: 2OA) is pleased to announce that it is advancing community engagement and permitting at the Alto Ruri Project (“Alto Ruri”) located approximately 15 kilometers (km) from Barrick’s past producing Pierina Gold Mine. The Company’s focus is to secure a long-term community agreement to systematically explore the high-sulphidation epithermal gold system at Alto Ruri. This district-scale system includes a 2 km by 1.5 km advanced argillic alteration zone that has never been systematically tested with modern geophysics and drilling. Historical drilling at Alto Ruri by Compañía de Minas Buenaventura in 1997 (12-hole 2,254.5m), as reported in the Company’s news release from March 4th, 2024, confirmed...

Continue reading

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and analytical approaches for CLD-401 are in alignment with FDA guidance; Calidi expects to file an IND by end of 2026 Partnered with Matica Bio around the GMP manufacturing of CLD-401 Presented new data on in situ T-cell engagers (TCEs) at 2026 AACR-IO conference Raised $6.5 million in public offering and ATM salesSAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent...

Continue reading

iAnthus Reports Fiscal Fourth Quarter and Full Year 2025 Financial Results

NEW YORK and TORONTO, March 27, 2026 (GLOBE NEWSWIRE) — iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCID: ITHUF), which owns, operates, and partners with regulated cannabis operations across the United States, today reported its financial results for the fourth quarter and year ended December 31, 2025. The Company’s Annual Report on Form 10-K (the “Annual Report”), which includes its audited consolidated financial statements for the year ended December 31, 2025 and the related management’s discussion and analysis of financial condition and results of operations, can be accessed on the Securities and Exchange Commission’s (“SEC’s”) website at www.sec.gov, on the System for Electronic Document Analysis and Retrieval’s (SEDAR+) website at www.sedarplus.com, and on the Company’s website at www.iAnthus.com....

Continue reading

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026 EB612, the first long-acting oral PTH peptide replacement tablet for patients with hypoparathyroidism – final variants selected, pre-IND initiatives underway with intention to file IND in late 2026 in partnership with OPKO EB618, the first Oral OXM (GLP-1/Glucagon) peptide tablet for patients with metabolic syndromes – PK/PD validation complete, intention to file IND pursuant to OPKO Phase 1 SAD/MAD SC injection data TEL AVIV, March 27, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today reported...

Continue reading

Presurance Holdings Reports 2025 Fourth Quarter Financial Results

TROY, Mich., March 27, 2026 (GLOBE NEWSWIRE) — Presurance Holdings, Inc. (Nasdaq: PRHI) (“Presurance” or the “Company”) today announced results for the fourth quarter ended December 31, 2025. Year-end 2025 Financial HighlightsPersonal Lines production up 12.7% on the year Commercial Lines were down 67% and continue to run off Personal lines production comprised 100% of gross written premiums in Q4 Commercial Lines – zero premium production for the fourth quarterWhile gross written premiums declined in the fourth quarter, as the Company continued its disciplined shift away from previously written commercial lines, on the other hand, personal lines premium was up 12.7% on the year, reflecting a concerted focus going forward. With the exit from commercial lines business on-going, the Company has meaningfully simplified its risk...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.